Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation

doi:10.4240/wjgs.v15.i12.2727

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1884)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

946

Figures (1-3)

173

Tables (1-4)

202

Sum=1377

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

104

Download

340

Sum=444

Dec 27, 2023 (publication date) through Nov 24, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Surg. Dec 27, 2023; 15(12): 2727-2738
Published online Dec 27, 2023. doi: 10.4240/wjgs.v15.i12.2727

Full Size Figure Download Figure

Figure 1 Long-term graft outcomes according to risk factors. A: Survival curves according to tacrolimus trough concentration at 24 wk post-liver transplantation (> 5.4 ng/mL, n = 45 vs ≤ 5.4 ng/mL n = 33). Patients for whom tacrolimus concentrations at 24 wk were not reported were excluded from the analyses; B: Survival curves for the antibody-mediated rejection (AMR, n = 6) and non-AMR (n = 83) groups. ABOi: ABO-incompatible; FK: Tacrolimus; LT: Liver transplantation; AMR: Antibody-mediated rejection.

Citation: Han JW, Choi JY, Jung ES, Kim JH, Cho HS, Yoo JS, Sung PS, Jang JW, Yoon SK, Choi HJ, You YK. Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation. World J Gastrointest Surg 2023; 15(12): 2727-2738
URL: https://www.wjgnet.com/1948-9366/full/v15/i12/2727.htm
DOI: https://dx.doi.org/10.4240/wjgs.v15.i12.2727